ACM
BMRN icon

AlphaCrest Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaCrest Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,264
Closed -$1.38M – 158
2022
Q3 		$1.38M Sell
16,264
-6,954
-30% -$619K 0.08% 414
2022
Q2 		$1.92M Sell
23,218
-33,387
-59% -$2.66M 0.09% 328
2022
Q1 		$4.36M Buy
56,605
+33,629
+146% +$2.81M 0.24% 63
2021
Q4 		$2.03M Sell
22,976
-1,665
-7% -$137K 0.08% 422
2021
Q3 		$1.91M Buy
24,641
+17,079
+226% +$1.35M 0.1% 330
2021
Q2 		$631K Sell
7,562
-46,348
-86% -$3.67M 0.03% 869
2021
Q1 		$4.07M Buy
53,910
+21,806
+68% +$1.78M 0.23% 93
2020
Q4 		$2.81M Buy
32,104
+16,017
+100% +$1.27M 0.23% 98
2020
Q3 		$1.22M Buy
16,087
+14,085
+704% +$1.43M 0.13% 197
2020
Q2 		$247K Sell
2,002
-3,831
-66% -$381K 0.04% 726
2020
Q1 		$493K Sell
5,833
-3,592
-38% -$310K 0.06% 580
2019
Q4 		$797K Sell
9,425
-18,069
-66% -$1.36M 0.07% 482
2019
Q3 		$1.85M Sell
27,494
-3,071
-10% -$237K 0.11% 267
2019
Q2 		$2.62M Buy
30,565
+17,089
+127% +$1.46M 0.23% 96
2019
Q1 		$1.2M Buy
13,476
+7,017
+109% +$650K 0.18% 136
2018
Q4 		$550K Buy
+6,459
New +$614K 0.16% 206

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AlphaCrest Capital Management's BMRN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 16,264 shares — an estimated $1.38M sold.

AlphaCrest Capital Management first reported a position in BMRN in Q4 2018 and held it in 16 quarters. The position peaked at $4.36M in Q1 2022. 581 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 16,264 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $1.38M.
  • AlphaCrest Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's BioMarin Pharmaceuticals position peaked at $4.36M in Q1 2022.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.